Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Ons... ( LEXINGTON Mass. May 5 /- IndevusP...)

HOME >> BIOLOGY >> TECHNOLOGY

Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty

Date:5/5/2008

LEXINGTON, Mass., May 5 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced positive results of the ongoing Phase III extension study of SUPPRELIN(R) LA (histrelin acetate), the only once-yearly subcutaneous implant for the treatment of central precocious puberty or early onset puberty, at the Lawson Wilkins Pediatric Endocrine Society (LWPES) Annual Meeting. This study evaluated the two-year safety and efficacy of SUPPRELIN LA in children who received a second implant following an initial year of therapy. The study found that SUPPRELIN LA demonstrated continued profound hormone suppression with no escapes (breakthrough of hormones) and led to continued decreases in rates of growth, skeletal maturation and body mass index at 24 months compared to 12 months.

"This study confirms that SUPPRELIN LA maintains remarkable suppression of peak hormone and sex steroid levels for two years in children with central precocious puberty and that the removal of the first implant and insertion of the second does not influence efficacy," said Gad Kletter, MD, Head of Pediatric Endocrinology, Swedish Medical Center, Seattle, WA. "While the frequent dosing of traditional injections may lead to issues with long-term compliance, SUPPRELIN LA offers patients, families and physicians a truly sustained treatment option that only requires action once a year."

"Central precocious puberty can be a devastating condition physically, psychologically and socially and is extremely difficult to manage," stated Bobby Sandage, Jr., Ph.D., Executive Vice President, Research and Development and Chief Scientific Officer, Indevus Pharmaceuticals. "We are encouraged by these recent findings and hope they provide an added level of comfo
'/>"/>

1

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting

Post Your Comments:

Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Ons...( LEXINGTON Mass. May 5 /- IndevusP...)